Project Description

Symetis

CEO: Jacques Essinger

Sector: Medtech, Cardiovascular
Location: Ecublens, Switzerland
Investment Stage: Growth
Investment Status: Acquired by Boston Scientific in 2017
Year Invested: 2016

Symetis

Symetis specialises in the development, manufacturing and marketing of next-generation percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions. 

Symetis was acquired by Boston Scientific in 2017. 

See Symetis related news here

Back to all companies

Endeavour Vision
Board Member

Dominik Ellenrieder

Dominik Ellenrieder

Damien Tappy

Damien Tappy